File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/1756-185X.13694
- Scopus: eid_2-s2.0-85071838021
- PMID: 31489783
- WOS: WOS:000485738000001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease‐modifying antirheumatic drugs
Title | Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease‐modifying antirheumatic drugs |
---|---|
Authors | |
Keywords | DMARD herpes zoster infliximab methotrexate rheumatoid arthritis |
Issue Date | 2020 |
Publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd |
Citation | International Journal of Rheumatic Diseases, 2020, v. 23 n. 2, p. 189-196 How to Cite? |
Abstract | Objectives:
To investigate the risk of cutaneous herpes zoster (HZ) in spondyloarthritis (SpA) compared with that in rheumatoid arthritis (RA), and in disease‐modifying antirheumatic drugs (DMARDs) used in SpA.
Method:
A total of 727 patients with an expert diagnosis of SpA were identified retrospectively from four rheumatology centers in Hong Kong. Electronic medical records from 1995 to 2018 were reviewed for incidence of cutaneous HZ and demographic data including age, sex, comorbidities, smoking and drinking status. DMARDs used included sulphasalazine, methotrexate, leflunomide, steroids, etanercept, infliximab, adalimumab, golimumab, secukinumab and ustekinumab. Cox regression models were used to evaluate hazard ratios (HRs) of different DMARDs in patients with SpA. Propensity score was used for matching and comparison with 857 patients with RA.
Results:
There were 23 cases of cutaneous HZ in patients with SpA and 59 cases in patients with RA. Among patients with SpA, 7 cases of cutaneous HZ may be attributed to sulfasalazine treatment, 7 to methotrexate, 2 to leflunomide, 2 to infliximab, 1 to etanercept, 2 to adalimumab, and 1 to secukinumab. Risks of cutaneous HZ were the same in SpA (stratified HR 0.97; 95% CI 0.58; 1.61; P = .89) and RA. Methotrexate (adjusted HR 3.47; 95% CI 1.25; 9.63; P = .02) and infliximab (adjusted HR 10.67; 95% CI 1.37; 82.88; P = .02) were found to be associated with HZ after adjustments for traditional risk factors.
Conclusion:
Risk of cutaneous HZ in SpA was not lower than in RA. Methotrexate and infliximab were associated with cutaneous HZ in SpA. |
Persistent Identifier | http://hdl.handle.net/10722/277163 |
ISSN | 2023 Impact Factor: 2.4 2023 SCImago Journal Rankings: 0.653 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, SCT | - |
dc.contributor.author | Li, IWS | - |
dc.contributor.author | Ng, AHY | - |
dc.contributor.author | Lau, CS | - |
dc.contributor.author | Chung, HY | - |
dc.date.accessioned | 2019-09-20T08:45:47Z | - |
dc.date.available | 2019-09-20T08:45:47Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | International Journal of Rheumatic Diseases, 2020, v. 23 n. 2, p. 189-196 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.uri | http://hdl.handle.net/10722/277163 | - |
dc.description.abstract | Objectives: To investigate the risk of cutaneous herpes zoster (HZ) in spondyloarthritis (SpA) compared with that in rheumatoid arthritis (RA), and in disease‐modifying antirheumatic drugs (DMARDs) used in SpA. Method: A total of 727 patients with an expert diagnosis of SpA were identified retrospectively from four rheumatology centers in Hong Kong. Electronic medical records from 1995 to 2018 were reviewed for incidence of cutaneous HZ and demographic data including age, sex, comorbidities, smoking and drinking status. DMARDs used included sulphasalazine, methotrexate, leflunomide, steroids, etanercept, infliximab, adalimumab, golimumab, secukinumab and ustekinumab. Cox regression models were used to evaluate hazard ratios (HRs) of different DMARDs in patients with SpA. Propensity score was used for matching and comparison with 857 patients with RA. Results: There were 23 cases of cutaneous HZ in patients with SpA and 59 cases in patients with RA. Among patients with SpA, 7 cases of cutaneous HZ may be attributed to sulfasalazine treatment, 7 to methotrexate, 2 to leflunomide, 2 to infliximab, 1 to etanercept, 2 to adalimumab, and 1 to secukinumab. Risks of cutaneous HZ were the same in SpA (stratified HR 0.97; 95% CI 0.58; 1.61; P = .89) and RA. Methotrexate (adjusted HR 3.47; 95% CI 1.25; 9.63; P = .02) and infliximab (adjusted HR 10.67; 95% CI 1.37; 82.88; P = .02) were found to be associated with HZ after adjustments for traditional risk factors. Conclusion: Risk of cutaneous HZ in SpA was not lower than in RA. Methotrexate and infliximab were associated with cutaneous HZ in SpA. | - |
dc.language | eng | - |
dc.publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd | - |
dc.relation.ispartof | International Journal of Rheumatic Diseases | - |
dc.rights | Preprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | - |
dc.subject | DMARD | - |
dc.subject | herpes zoster | - |
dc.subject | infliximab | - |
dc.subject | methotrexate | - |
dc.subject | rheumatoid arthritis | - |
dc.title | Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease‐modifying antirheumatic drugs | - |
dc.type | Article | - |
dc.identifier.email | Li, IWS: liws03@hku.hk | - |
dc.identifier.email | Lau, CS: cslau@hku.hk | - |
dc.identifier.email | Chung, HY: jameschy@hku.hk | - |
dc.identifier.authority | Lau, CS=rp01348 | - |
dc.identifier.authority | Chung, HY=rp02330 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1111/1756-185X.13694 | - |
dc.identifier.pmid | 31489783 | - |
dc.identifier.scopus | eid_2-s2.0-85071838021 | - |
dc.identifier.hkuros | 305554 | - |
dc.identifier.volume | 23 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 189 | - |
dc.identifier.epage | 196 | - |
dc.identifier.isi | WOS:000485738000001 | - |
dc.publisher.place | Australia | - |
dc.identifier.issnl | 1756-1841 | - |